Mounjaro and Heart Rate: Why Tirzepatide Raises Your Pulse (and What It Means) (2026)

A small rise in resting heart rate is a recognized, labeled effect of tirzepatide, the dual GIP and GLP-1 receptor agonist sold as Mounjaro. On average it is modest — roughly two to five beats per minute — and for most people it is asymptomatic, something seen on a monitor rather than felt.^[1] The cardiovascular picture for tirzepatide, however, is told with more caution than for older GLP-1 drugs: tirzepatide does not yet have a completed dedicated cardiovascular outcomes trial. The large SURPASS-CVOT study is still ongoing, with results anticipated. What we do have is reassuring on risk factors — across the SURPASS and SURMOUNT programs, and in the high-cardiovascular-risk population of SURPASS-4, tirzepatide improved weight, blood pressure, lipids, and glucose, and showed no signal of cardiovascular harm.^[2] But that is different from a proven reduction in heart attacks and strokes, so this guide is precise about what is established versus pending. It also separates the small average pulse rise from palpitations as a symptom, which can instead point to dehydration, low blood sugar, anxiety, or an arrhythmia. Mounjaro is tirzepatide (the same molecule as Zepbound); see our Mounjaro drug page, and for the closely related semaglutide story see heart rate on semaglutide. This is general educational information, not medical advice — your prescriber manages your care.

Does Mounjaro raise your heart rate?

Yes — modestly. A small increase in resting heart rate is a recognized, labeled effect of tirzepatide and is described in the clinical-pharmacology and adverse-reaction context of the prescribing information. Across the clinical program the average rise lands in the range of roughly two to five beats per minute, in line with what is seen across the incretin receptor agonist class.^[1] The key word is average: a few-beat shift in a population mean is small, and for most individuals it is not something they notice. It does not, on its own, mean your heart is under strain.

Because Mounjaro and Zepbound are the same molecule — tirzepatide — the same mechanism applies across both products; the practical difference is the approved indication and dosing. As with most tirzepatide effects, the change is typically modest and asymptomatic, identified on a blood-pressure cuff or heart-rate monitor rather than felt as a symptom.^[1] That framing matters for the rest of this guide, because the felt sensation of a racing or pounding heart — palpitations — is a separate issue we cover below, and it is not the same thing as the small average rise the label describes.

Why tirzepatide raises your pulse

The honest answer is that the exact mechanism is not fully settled. The leading explanation is that incretin receptor agonists — including tirzepatide's dual GIP and GLP-1 action — can mildly increase heart rate through autonomic effects: a small shift in the balance of sympathetic and parasympathetic input to the heart's natural pacemaker, the sinus node, that nudges the resting rate upward. The prevailing view is that the drug's action on regions involved in cardiovascular and autonomic regulation produces this small chronotropic (heart-rate) effect rather than any direct toxic action on heart muscle.^[1] Researchers have not pinned down a single definitive pathway, so this is best understood as a plausible, partly-characterized mechanism rather than a closed question.

It is also worth noting what the heart-rate rise is not. It is not the same as the palpitations some people feel, which usually have a different driver — dehydration, low blood sugar, anxiety, or an arrhythmia — covered in a later section. And the small mean rise is not, by itself, a marker of cardiovascular harm, which is where the evidence on tirzepatide and the heart comes in — along with an important caveat about what has and has not yet been proven.

The evidence nuance: risk factors improved, but the outcomes trial is still pending

Here is where tirzepatide's story differs from semaglutide's, and where precision matters. For semaglutide, dedicated cardiovascular outcome trials (SUSTAIN-6 and SELECT) have already finished and showed a reduction in major adverse cardiovascular events. Tirzepatide does not yet have a completed equivalent. Its dedicated cardiovascular-outcomes trial, SURPASS-CVOT, is ongoing, and its hard-outcome results (cardiovascular death, heart attack, stroke) are anticipated, not yet reported. So it would be inaccurate to claim tirzepatide has proven it reduces those events the way semaglutide's SELECT trial did.

What the existing data do show is reassuring on the things that drive cardiovascular risk. In the SURPASS-4 trial — which studied tirzepatide specifically in people with type 2 diabetes and increased cardiovascular risk — tirzepatide improved glucose control and was associated with favorable changes in weight, blood pressure, and lipids, with no signal of cardiovascular harm in the prespecified safety analysis.^[2] Improvements across that cluster of risk factors are encouraging, and they are why clinicians do not treat the small heart-rate rise as a reason to fear the drug.

A small heart-rate rise vs palpitations as a symptom

It is important to separate the small average heart-rate rise — typically silent, seen on a monitor — from a racing, pounding, fluttering, or skipping heartbeat that you actually feel, which is what people mean by palpitations. The first is the labeled effect described above. The second is a symptom, and it often has nothing to do with the small chronotropic effect and instead reflects a fixable driver:

• Dehydration. The gastrointestinal side effects of tirzepatide — nausea, vomiting, diarrhea — can cause fluid loss, and dehydration commonly speeds the heart and produces a pounding sensation, often with dizziness or lightheadedness on standing.^[1]
• Low blood sugar (hypoglycemia). Low glucose can cause a fast, pounding heartbeat alongside shakiness, sweating, and difficulty concentrating. The risk is higher when tirzepatide is combined with insulin or a sulfonylurea.^[1]
• Anxiety. A racing heart is one of the most common physical features of anxiety and can be mistaken for a drug effect, particularly when someone is newly attentive to their heart.
• An arrhythmia. Palpitations can occasionally signal an abnormal heart rhythm — for example atrial fibrillation — which is a separate medical issue that deserves evaluation rather than something to attribute to the drug by default.

The practical upshot: a felt racing or irregular heartbeat is worth reporting to your prescriber, because the most useful response is to look for the actual cause — hydration, glucose, anxiety, or rhythm — rather than to assume it is simply the expected average rise.

When a fast heart rate is a red flag

In short, the severity, the persistence, and the company a fast heartbeat keeps are what move it from "expected" to "get it checked." A pulse that is briefly a few beats faster and otherwise silent is the ordinary pattern; a sustained high rate, an irregular rhythm, or palpitations bundled with chest pain, breathlessness, or fainting are the signals that need attention.

What it means for you — and what to do

For most people the answer is reassuringly simple: no action is needed beyond awareness. The following are general, commonly-discussed points — all of them are prescriber-directed. Do not change your Mounjaro dose, start supplements, or adjust other medications on your own.

• Most people need do nothing. A small, asymptomatic rise in resting heart rate is an expected, labeled effect, and the available data show tirzepatide improves cardiovascular risk factors with no signal of harm. It is not a reason to stop or fear the drug on its own.^[1][2]
• Monitor more closely if you have heart disease. If you have established cardiovascular disease, a known arrhythmia, or take rate- or rhythm-affecting medications, your prescriber may want to keep an eye on your heart rate and tailor the plan accordingly — so make sure they know your history. This is especially worth discussing while the dedicated outcomes trial (SURPASS-CVOT) is still pending.
• Manage dehydration and low blood sugar. Because both can speed the heart, keep fluids and electrolytes steady (especially during any nausea, vomiting, or diarrhea), eat regular balanced meals, and follow your clinician's plan for treating lows — particularly if you use insulin or a sulfonylurea.^[1]
• Discuss it if you feel it. If you actually feel a racing, pounding, or irregular heartbeat — as opposed to merely reading a slightly higher number — tell your prescriber so the real cause (hydration, glucose, anxiety, or rhythm) can be sorted out.

For the basics of the medication itself, see the Mounjaro drug page, and for the closely related semaglutide story — where the cardiovascular outcome trials are already complete — see heart rate on semaglutide. If you are choosing where to start or continue tirzepatide under proper supervision, a legitimate provider reviews your cardiovascular history, titrates you on the label schedule, and follows up on effects like heart rate — exactly the monitoring that keeps treatment safe.